Gilead Sciences' move to launch generic versions of two hepatitis C treatments could motivate states to eliminate restrictions on their Medicaid and inmate populations.
The U.S. House of Representatives and Senate have both passed measures to halt the use of "gag clauses" by insurers and pharmacy benefit managers. President Donald Trump is expected to sign the bills soon.
An analysis of brand-name prescription drug prices shows it's been business as usual for drugmakers, with far more price hikes than cuts. The number of increases slowed somewhat and were not quite as steep as in past years.
Gilead will start selling the generics for chronic hepatitis C in January at a $24,000 list price, a significant discount compared to the price for its branded alternatives, which can cost nearly $100,000 for a full course of treatment.
The results from a new clinical trial raise more doubts about the daily use of aspirin to prevent the onset of cardiovascular disease.
Combination drugs ideally reduce the number of pills a patient has to take and improve adherence. But that doesn't happen if branded drugs are prohibitively expensive—in 2016 they cost Medicare $925 million more than generic alternatives.
The large price increases on brand name drugs and the high prices of new specialty drugs are driven by a desire for greater profits and not by the cost of research.
The high prices for specialty drugs are forcing physicians, patients and their families to factor in financial toxicity when choosing an appropriate therapy.
The Senate Finance Committee's first formal hearing on drug prices with HHS Secretary Alex Azar failed to firm up policy goals even as heightened congressional scrutiny puts drugmakers on edge.
A panel that advises Congress and HHS on Medicaid policy recommended tweaking the Medicaid drug rebate program to reduce spending on drugs by hundreds of millions of dollars.
Although more generic drugs are coming through the pipeline, generic competition won't affect 46% of the estimated sales revenue of the top 100 drugs through 2023, according to a new report.
Eighty percent of nearly 750 providers, payers and pharmaceutical companies polled said they are optimistic that the new health system-led generic-drug company will change the status quo, and 90% said they would buy drugs from it, according to a new survey.